Skip to main content

OIC

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Alkermes
AlkermesDUBLIN 4, Ireland
1 program
1
ALKS 37Phase 21 trial
Active Trials
NCT01418092Completed91Est. Jun 2012
Theravance Biopharma
1 program
1
TD-1211 IV [C14]Phase 11 trial
Active Trials
NCT01702194Completed10Est. Mar 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AlkermesALKS 37
Theravance BiopharmaTD-1211 IV [C14]

Clinical Trials (2)

Total enrollment: 101 patients across 2 trials

ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)

Start: Sep 2011Est. completion: Jun 201291 patients
Phase 2Completed

TD-1211 IV/Oral Mass Balance Study

Start: Nov 2012Est. completion: Mar 201310 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.